Why Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Stock Should Not Be Taken For Granted By Investors In 2024
In the last trading session, 3.51 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) were traded, and its beta was 0.80. Most recently the company’s